^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SLAMF7 FPBMC

i
Associations
Company:
University of Virginia
Drug class:
CS-1 inhibitor, CD3 inhibitor
Associations
12ms
Trial completion date • Trial primary completion date
|
SLAMF7 (SLAM Family Member 7)
|
SLAMF7 FPBMC
1year
MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, University of Virginia | N=18 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
SLAMF7 (SLAM Family Member 7)
|
SLAMF7 FPBMC
over1year
MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2; Trial completion date: Jan 2030 --> May 2030 | Trial primary completion date: Jan 2027 --> May 2027
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over1year
MM BATs: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2; Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jun 2028 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Jan 2027
Trial completion date • Trial primary completion date • Phase classification • Enrollment open
|
IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over2years
MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1; Trial completion date: Jan 2027 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2027
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over3years
New P1 trial • Clinical
|
IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC